Vitreous inflammatory factors and serous retinal detachment in central retinal vein occlusion: A case control series

Journal of Inflammation

Volumn 8, Issue , 2011, Pages

  Noma, Hidetaka ^a   Funatsu, Hideharu ^a   Mimura, Tatsuya ^b   Eguchi, Shuichiro ^c  

^a Tokyo Women s Medical University   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Eguchi Eye Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN C;

AGED; ARTICLE; CASE CONTROL STUDY; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTOID RETINA MACULA EDEMA; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA EDEMA; SEROUS RETINAL DETACHMENT; THICKNESS; VITRECTOMY; VITREOUS BODY;

CYSTOIDEA;

EID: 83155178481     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-8-38     Document Type: Article

References (35)

1. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Green WR, Chan CC, Hutchins GM, Terry JM, Trans Am Ophthalmol Soc 1981 79 371 422 7342407
2. Classification of central retinal vein occlusion. Hayreh SS, Ophthalmology 1983 90 458 474 6877778 (Pubitemid 13059774)
3. Serous macular detachment in central retinal vein occlusion. Ozdemir H, Karacorlu M, Karacorlu S, Retina 2005 25 561 563 10.1097/00006982-200507000- 00003 16077350 (Pubitemid 41077257)
4. Serous retinal detachment associated with retinal vein occlusion. Tsujikawa A, Sakamoto A, Ota M, Kotera Y, Oh H, Miyamoto K, Kita M, Yoshimura N, Am J Ophthalmol 2010 149 291 301 e5 10.1016/j.ajo.2009.09.007 20103055
5. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Dvorak HF, Brown LF, Detmar M, Dvorak AM, Am J Pathol 1995 146 1029 1039 7538264
6. Vascular Endothelial Growth Factor and Interleukin-6 are Correlated With Serous Retinal Detachment in Central Retinal Vein Occlusion. Noma H, Funatsu H, Mimura T, Curr Eye Res 2012 37 62 67 21978265
7. Aqueous vascular endothelial growth factor levels are associated with serous macular detachment secondary to branch retinal vein occlusion. Park SP, Ahn JK, Mun GH, Retina 2010 30 281 286 10.1097/IAE.0b013e3181b9f153 19881397
8. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP, Science 1999 285 245 248 10.1126/science.285.5425.245 10398599 (Pubitemid 29329995)
9. VEGF increases retinal vascular ICAM-1 expression in vivo. Lu M, Perez VL, Ma N, Miyamoto K, Peng HB, Liao JK, Adamis AP, Invest Ophthalmol Vis Sci 1999 40 1808 1812 10393052 (Pubitemid 29297158)
10. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma JX, Faseb J 2006 20 323 325 16368716 (Pubitemid 46671158)
11. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida H, Oshima Y, Ueno A, Hata Y, Yoshida H, Ishibashi T, PLoS One 2009 4 8158 10.1371/journal.pone.0008158 19997642
12. Two functional forms of vascular endothelial growth factor receptor-2/Flk-1 mRNA are expressed in normal rat retina. Wen Y, Edelman JL, Kang T, Zeng N, Sachs G, J Biol Chem 1998 273 2090 2097 10.1074/jbc.273.4.2090 9442048 (Pubitemid 28069257)
13. Modulation and function of intercellular adhesion molecule-1 (CD54) on human retinal pigment epithelial cells. Elner SG, Elner VM, Pavilack MA, Todd RF, Mayo-Bond L, Franklin WA, Strieter RM, Kunkel SL, Huber AR, Lab Invest 1992 66 200 211 1346541
14. Circulating adhesion molecules in disease. Gearing AJ, Newman W, Immunol Today 1993 14 506 512 10.1016/0167-5699(93)90267-O 7506035 (Pubitemid 23301002)
15. ICAM-1 signaling in endothelial cells. Lawson C, Wolf S, Pharmacol Rep 2009 61 22 32 19307690
16. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, George L, King GL, N Engl J Med 1994 331 1480 1487 10.1056/NEJM199412013312203 7526212 (Pubitemid 24356306)
17. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension, J Hypertens 1999 17 151 183 10067786
18. Baseline and early natural history report. The Central Vein Occlusion Study, Arch Ophthalmol 1993 111 1087 1095 7688950
19. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report, Ophthalmology 1995 102 1425 1433 9097788
20. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group, Arch Ophthalmol 1997 115 486 491 9109757
21. Tomographic assessment of vitreous surgery for diabetic macular edema. Otani T, Kishi S, Am J Ophthalmol 2000 129 487 494 10.1016/S0002-9394(99)00409-2 10764858 (Pubitemid 30184920)
22. Vitreous inflammatory factors in macular edema with central retinal vein occlusion. Noma H, Funatsu H, Harino S, Mimura T, Eguchi S, Hori S, Jpn J Ophthalmol 2011 55 248 255 10.1007/s10384-011-0016-4 21538003
23. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Noma H, Funatsu H, Mimura T, Eguchi S, Shimada K, Hori S, Curr Eye Res 2011 36 256 263 10.3109/02713683.2010.513090 21275514
24. Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion. Noma H, Funatsu H, Mimura T, Eguchi S, Shimada K, Br J Ophthalmol 2011 95 788 792 10.1136/bjo.2010.192468 21109696
25. Effects of VEGFR-1, VEGFR-2, and IGF-IR hammerhead ribozymes on glucose-mediated tight junction expression in cultured human retinal endothelial cells. Spoerri PE, Afzal A, Li Calzi S, Shaw LC, Cai J, Pan H, Boulton M, Grant MB, Mol Vis 2006 12 32 42 16446700 (Pubitemid 43072829)
26. EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. Ojima T, Takagi H, Suzuma K, Oh H, Suzuma I, Ohashi H, Watanabe D, Suganami E, Murakami T, Kurimoto M, Honda Y, Yoshimura N, Am J Pathol 2006 168 331 339 10.2353/ajpath.2006.050435 16400034 (Pubitemid 43062584)
27. Decursin inhibits VEGF-mediated inner blood-retinal barrier breakdown by suppression of VEGFR-2 activation. Kim JH, Lee YM, Ahn EM, Kim KW, Yu YS, J Cereb Blood Flow Metab 2009 29 1559 1567 10.1038/jcbfm.2009.78 19536074
28. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. Scheppke L, Aguilar E, Gariano RF, Jacobson R, Hood J, Doukas J, Cao J, Noronha G, Yee S, Weis S, Martin MB, Soll R, Cheresh DA, Friedlander M, J Clin Invest 2008 118 2337 2346 18483622 (Pubitemid 351872350)
29. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, Tong PY, Proc Natl Acad Sci USA 2004 101 6605 6610 10.1073/pnas.0308342101 15096582 (Pubitemid 38586021)
30. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Wang K, Wang Y, Gao L, Li X, Li M, Guo J, Biol Pharm Bull 2008 31 1541 1546 10.1248/bpb.31.1541 18670086
31. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC, Diabetes 2008 57 1026 1033 10.2337/db07-0982 18174522
32. Retinoic acid and dexamethasone regulate the expression of PEDF in retinal and endothelial cells. Tombran-Tink J, Lara N, Apricio SE, Potluri P, Gee S, Ma JX, Chader G, Barnstable CJ, Exp Eye Res 2004 78 945 955 10.1016/j.exer.2003.12.013 15051476 (Pubitemid 38402203)
33. Vitrectomy for macular edema combined with retinal vein occlusion. Tachi N, Hashimoto Y, Ogino N, Doc Ophthalmol 1999 97 465 469 10.1023/A:1002432032354 10896365
34. Vitrectomy with complete posterior hyaloid removal for ischemic central retinal vein occlusion: series of cases. Leizaola-Fernandez C, Suarez-Tata L, Quiroz-Mercado H, Colina-Luquez J, Fromow-Guerra J, Jimenez-Sierra JM, Guerrero-Naranjo JL, Morales-Canton V, BMC Ophthalmol 2005 5 10 10.1186/1471-2415-5-10 15943889 (Pubitemid 41074246)
35. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY, Ophthalmology 2010 117 1124 1133 e1 10.1016/j.ophtha.2010.02.022 20381871